Non–clear cell renal cell carcinoma has a poor prognosis and limited treatment options. Recently, the advent of molecular genomics, along with an advanced understanding of the underlying drivers of tumorigenesis, has ushered in an era of novel trial design with a growing number of available therapies.
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
The use of artificial intelligence (AI) was a central theme at the 2024 ASCO Annual Meeting, including many tools, such as large language models, clinical…
Key PointsLymphopenia is transient with a persistent lack of effector B cells causing no excess late infectious mortality after R-CHOP for HIV-DLBCL.R-IPI,
Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication…
Email from American Head and Neck Society This year, many of our AHNS Sections and Services have been working tirelessly to deliver top-notch educational…
The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.
A 65-year-old woman presented with a 6-month history of postmenopausal vaginal bleeding, and endometrial biopsy showed grade 2 endometrioid adenocarcinoma. What would you do next?
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured…
